Last checked at 30 Dec 2021 11:20
genedrive plc
("genedrive" or the "Company")
Result of AGM
genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces that at the Annual General Meeting, held today, all resolutions proposed were duly passed.
For information, details of the proxy voting are shown below:
Resolutions | Votes For | Vote For (as % of votes cast) | Votes Against | Votes Against (as % of votes cast) | Vote Withheld |
1 | 10,597,308 | 99.5% | 49,547 | 0.5% | 250,964 |
2 | 10,450,162 | 96.6% | 371,359 | 3.4% | 76,298 |
3 | 10,432,244 | 96.2% | 409,436 | 3.8% | 56,139 |
4 | 10,432,244 | 96.2% | 409,436 | 3.8% | 56,139 |
5 | 10,341,865 | 95.5% | 491,145 | 4.5% | 64,809 |
6 | 10,420,244 | 96.1% | 421,436 | 3.9% | 56,139 |
7 | 9,277,547 | 95.8% | 409,436 | 4.2% | 1,210,836 |
8 | 10,529,866 | 97.2% | 301,290 | 2.8% | 66,663 |
9 | 10,396,600 | 96.0% | 429,809 | 4.0% | 71,410 |
10 | 9,237,043 | 87.3% | 1,342,164 | 12.7% | 318,612 |
The full text of each of the resolutions is set out in the notice of Annual General Meeting, copies of which are available on the Company's website (www.genedriveplc.com).
For further details please contact:
genedrive plc | +44 (0)161 989 0245 |
David Budd: CEO / Matthew Fowler: CFO | |
Peel Hunt LLP (Nominated Adviser and Joint Broker) | +44 (0)20 7418 8900 |
James Steel | |
finnCap (Joint Broker) | +44 (0)20 7220 500 |
Geoff Nash / Kate Bannatyne / Alice Lane | |
Walbrook PR Ltd (Media Relations & IR) | +44 (0)20 7933 8780 or genedrive@walbrookpr.com |
Paul McManus | +44 (0)7980 541 893 |
About genedrive plc - www.genedriveplc.com
genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, certain military biological targets and a high throughput SARS-CoV-2 assay. The Company has also recently released a test to help in the prevention of hearing loss (Genedrive® MT-RNR1 Kit) caused by specific antibiotics in neonates.